BioCentury
ARTICLE | Clinical News

Achillion reports preliminary data from a Phase II trial of ACH-4471 for C3 glomerulopathy

December 1, 2017 9:41 PM UTC

Achillion Pharmaceuticals Inc. (NASAQ:ACHN) said preliminary data from the first 2 patients in a Phase IIa trial to treat complement 3 (C3) glomerulopathy (C3G) showed ACH-4471 reduced albumin-to-creatinine ratio from baseline to day 17 by 56% in the first patient and by 55% in the second patient. ACH-4471 also reduced each patient's ratios of fragment to intact C3 from baseline to day 14 by 64% and 28%, respectively.

The open-label, Australian trial will enroll about 10 patients with C3G or immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN) to receive multiple dose levels of oral ACH-4471 for 14 days followed by a 7-day taper. The first 2 patients received 100 mg ACH-4471 thrice daily. ...